The veterinary-grade API Albumini Tannas (Tannalbin) is a water-insoluble protein–polyphenol complex produced by controlled precipitation of egg albumin with tannic acid; the resulting amorphous powder is supplied as a brown-to-tan material with a characteristic astringent profile. The substance is not a single molecular entity, and release specifications are therefore built around total polyphenol content expressed as tannic acid equivalents, residual moisture, ash, microbiological quality, and particle-size distribution rather than a single purity value. The product is intended for incorporation into tablets, hard gelatin capsules, oral powders, granules, premixes, and oral suspensions; a true aqueous solution is not feasible because the complex is practically insoluble in water. Injectable preparations are possible only as suspensions or after qualification of a solvent system that maintains chemical integrity. The product is not distributed under a universal model designation; commercial presentations are differentiated by particle size, microbiological grade, and endotoxin load. The designation “veterinary grade” does not imply a single specification; it indicates that the material is manufactured and released under current GMP aligned with ICH Q7, with additional control of elemental impurities and residual solvents appropriate to target species. The CAS registry number for albumin tannate is 9006-50-2. Tannalbin is a synonym for the same complex, and the product should be distinguished from free tannic acid, hydrolyzable tannins, and mineral adsorbents used in antidiarrheal therapy.

Specification Targets and Analytical Anchors Across Seven Veterinary Dosage Forms

The relevant specification parameters change with the intended dosage form. For oral solid dosage forms, particle-size distribution is controlled by sieve analysis according to USP <786> or laser diffraction according to ISO 13320:2020; a direct-compression grade is typically specified with D90 below 250 µm, while a dry-blend powder for oral administration may require D90 below 150 µm to avoid gritty mouthfeel. Loss on drying is determined by USP <731> or equivalent, and residue on ignition is determined by USP <281>. Tannic acid content is commonly controlled as total polyphenols expressed as tannic acid equivalents on the dried basis; published supplier and pharmacopoeial intervals usually fall near 40–55%, but the exact range must be taken from the specific monograph or qualified supplier certificate. Microbiological quality for non-sterile oral grades follows harmonized acceptance criteria for non-sterile pharmaceutical substances, with total aerobic microbial count and total yeast and mold count established under Ph. Eur. 2.6.12 and USP <61>. For parenteral-grade material, a bacterial endotoxin limit is applied using USP <85> or Ph. Eur. 2.6.14.

For direct-compression tablet manufacture, the powder’s poor flowability and low bulk density are the principal processing constraints. The material is not a free-flowing crystalline API; flow through a 15 mm orifice is generally poor unless dry granulation or wet granulation is used, and bulk density values below 0.25 g/mL may create weight variation on high-speed rotary presses. On a 16-station rotary tablet press, acceptable weight variation and crushing strength require addition of a direct-compression filler such as microcrystalline cellulose and a glidant such as colloidal silicon dioxide at 0.5–1.5% w/w. Wet granulation with a high-shear mixer demands careful water addition because the API is water-insoluble and does not dissolve to form a binder solution; a separate binder such as povidone K30 at 2–5% w/w is generally required. High-shear mixing should be stopped when the granulate reaches a defined torque end-point rather than a fixed time, because batch-to-batch variability in protein–polyphenol hydration changes granule density. The dried granulate should be milled through a 0.8–1.5 mm screen; oversized particles increase disintegration time in the finished tablet. Punch lubrication with magnesium stearate should be kept at the minimum effective level, usually 0.5–1.0% w/w, because hydrophobic lubricant film can delay disintegration and reduce astringent availability.

Does Heat Sterilization Cleave the Tannin–Albumin Complex in Injectable Preparations?

Injectable presentation introduces the highest risk of chemical change because the protein–polyphenol complex is exposed to moist heat and pH shifts. The formulation is prepared as a sterile suspension, not a solution, because the active substance is practically insoluble in water and common parenteral solvents. Particle-size reduction for injectable suspensions must be performed under endotoxin-controlled conditions; jet milling is preferred over ball milling because the lower thermal load reduces risk of tannin release. Terminal sterilization by moist heat is evaluated with a sterilization cycle equivalent to 121 °C for 15 min under ISO 17665-1:2024, or a qualified alternative. After terminal sterilization, the finished suspension must be sampled for visible agglomeration, redispersibility, pH shift, total tannin content, and free tannic acid. Published data for autoclaved albumin tannate suspensions are limited; because of this, the product cannot be assumed terminally sterilizable without full validation on the specific container-closure system and batch formula. Aseptic processing is an alternative when terminal sterilization is not feasible, but the API is not inherently sterile, and bioburden reduction before aseptic filling is required. The container-closure system should be selected to minimize moisture uptake; butyl rubber stoppers with low water-vapor transmission are appropriate, and the headspace should be purged with nitrogen if oxidative darkening is observed at elevated temperature.

In oral powders and premixes, segregation and dusting are the main batch-scale risks. The API is a low-density amorphous powder with variable electrostatic charging; when blended with coarse mineral carriers such as limestone or dextrose monohydrate, the fine fraction may segregate vertically in the tote under vibration. Ribbon blenders and V-blenders with an intensifier bar are used for low-shear blending, but blend sampling must follow a statistically justified protocol such as stratified thief sampling at defined locations. Mix uniformity acceptance is based on the relative standard deviation of assay results; a typical release criterion is not more than 5.0% RSD across sampling points. If the blend is packaged as a multi-dose oral powder for feed or drinking water, the carrier particle-size distribution should overlap the API to reduce separation. Granulation is preferred when free-flowing dosing is required, because the uncompressed API alone is not suitable for automatic stick-pack filling. Granule production by wet granulation with purified water or an aqueous binder produces a denser product with a bulk density above 0.45 g/mL, but the granule must be dried to a moisture content that does not promote mold growth. Stability studies should include 25 °C/60% RH and 40 °C/75% RH storage according to ICH Q1A(R2) and should monitor color, water activity, and microbiological load.

When a Liquid Oral Suspension or Drinking-Water Premix Is Required

Formulation of a liquid oral product with Albumini Tannas requires an understanding that the API is practically insoluble in water and will form a sedimenting suspension rather than a true solution. Oral suspensions are typically prepared by dispersing a micronized or spray-dried grade in an aqueous vehicle containing a suspending agent such as microcrystalline cellulose/carboxymethylcellulose sodium or xanthan gum at 0.2–0.5% w/w. The pH of the finished suspension is usually adjusted to 5.0–7.0 because extreme pH values can hydrolyze the complex and release free tannic acid. Preservative efficacy is verified by USP <51> and should be repeated when the suspending polymer type or concentration changes, because tannin–polymer interactions can reduce the free preservative fraction. For drinking-water administration in poultry or swine, the formulation must remain redispersible after settling; sedimentation volume and resuspendability are controlled by measuring the settled bed height at defined time points and by rheological yield stress. Neither the API sedimentation volume nor the re-dispersibility can be predicted from supplier particle-size data alone; published data for drinking-water formulations at commercial concentrations are limited. A field-use concentration range for oral suspensions is generally established by dose titration studies in the target species, with a maximum total daily dose controlled by the astringent exposure and withholding periods set by regulatory authorities.

For bioequivalence or therapeutic equivalence evaluation in veterinary products, dissolution testing of Albumini Tannas is complicated by the fact that the active moiety is a heterogeneous protein–polyphenol complex rather than a defined solvated drug. A standard single-point dissolution method using USP <711> apparatus II may overestimate or underestimate available tannin because the complex remains suspended rather than dissolved. A modified two-phase release test using simulated gastric fluid and simulated intestinal fluid with pH change is therefore recommended when comparing formulations. Tannic acid equivalents in the release medium are quantified by UV-vis spectrophotometry or high-performance liquid chromatography with gallic acid as a reference standard, but the protein–polyphenol conjugate may not migrate as a single peak. Because the complex is not absorbable as an intact molecule, systemic exposure is low; the clinical effect is largely local in the gastrointestinal tract. This local mechanism reduces the need for plasma pharmacokinetic modeling and shifts release control toward astringent fraction available in the target intestinal segment. Published data for in vitro–in vivo correlation of Albumini Tannas veterinary products are limited, and dissolution specifications are generally established from batch history rather than from a validated IVIVC.

Stability studies for Albumini Tannas should be conducted with moisture-resistant packaging because the amorphous complex is hygroscopic and darkens upon moisture uptake. Blister packs with aluminum foil are preferred over high-density polyethylene bottles in humid zones; if HDPE bottles are used, the desiccant load and heat-seal liner must be qualified. Long-term storage is commonly evaluated at 25 °C/60% RH and accelerated at 40 °C/75% RH. The stability-indicating method should separate free tannic acid from bound tannin; simple total polyphenol assays may fail to detect hydrolysis of the complex. Water activity measured by chilled-mirror dew point apparatus should remain below 0.6 for oral powders; above this threshold, microbial growth risk increases and flowability decreases. Open-container stability of premix in feed or drinking water is not a property of the API alone; the user must validate in-use stability with the final feed matrix under ICH Q1A(R2) or regional guidance.

Species-Specific Limits for Elemental Impurities Are Not Uniform Across Global Veterinary Pharmacopoeias

For an API intended for veterinary use, elemental impurities are controlled under the principles of ICH Q3D as adapted by regional guidance, but the species-specific permissible daily exposures for many elements are not identical to human pharmaceutical limits. Lead, cadmium, arsenic, and mercury are generally controlled to the lowest practical levels by ICP-MS or ICP-OES, and the method is validated according to ICH Q2(R2). Because the API is produced from natural egg albumin and plant-derived tannic acid, incoming raw material variability is a greater source of element load than downstream synthesis. Supplier certificates for each albumin and tannin lot should therefore be reviewed, and the finished API should be tested for total heavy metals in addition to specific element profiling. Residual solvents are controlled under Ph. Eur. 2.4.24 or USP <467> when organic solvents are used in precipitation or washing. If the material is dried by tray, fluid-bed, or vacuum drying, drying temperature must be controlled below the denaturation point of the protein fraction; excessive temperature can darken the product and change its dissolution profile. A maximum product temperature below 80 °C is a conservative processing boundary; published data for the exact degradation threshold of the finished complex are limited.